Law360 (July 16, 2010, 12:25 PM EDT) -- EpiPen maker King Pharmaceuticals Inc. has lodged a complaint against Novartis AG's Sandoz Inc. unit, seeking to block the generic-drug maker from making and selling its own version of the epinephrine auto-injector.
King filed suit Wednesday in the U.S. District Court for the District of New Jersey, accusing Sandoz of infringing U.S. Patent Number 7,449,012 B2 by seeking U.S. Food and Drug Administration Approval to launch a generic version of EpiPen prior to the patent's 2025 expiration.
The plaintiff acquired rights to EpiPen, an auto-injector used to prevent potentially life-threatening allergic reactions to food or insect stings, in 2003 as part...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!